Gemtesa (vibegron) is a small molecule pharmaceutical. Vibegron was first approved as Gemtesa on 2020-12-23. It is used to treat overactive urinary bladder in the USA. The pharmaceutical is active against beta-3 adrenergic receptor. Gemtesa's patents are valid until 2030-12-01 (FDA).
|Indication||overactive urinary bladder|
|Drug Class||Beta 3 adrenoreceptor agonist|